• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Noah C. Choi, MD, DMRT

Professor, Department of Radiation Oncology, Harvard Medical School

Director of Radiation Oncology, MGH Thoracic Oncology Center, Massachusetts General Hospital

Contact Info

Noah Choi
Massachusetts General Hospital
55 Fruit St
Boston, MA, 02114
Mailstop: Radiation Oncology
Phone: 617-726-5184
Fax: 617-726-3603
nchoi@partners.org

Assistant

Not Available.

DF/HCC Program Affiliation

Lung Cancer

Research Abstract

Major Research Focus:

1) Intensity Modulated (IM) Proton vs. IM Photon Radiation Therapy for Lung Cancer:
The maximum tolerated dose (MTD) of intensity modulated (IM) proton and IM photon radiation will be determined in chemo-radiotherapy for medically inoperable stage I and II, and stage III non-small cell lung cancer. This will be followed by a phase III trial to compare IM proton with IM photon at their MTD local tumor control and survival in stage III non-small cell lung cancer.

2) FDG PET Study for Dose-Response Relationship between Residual FDG Uptake 10-12 Days after RT of Chemo-Radiotherapy and Subsequent Tumor Control at 12 months in Inoperable Lung Cancer: To determine residual glucose metabolic rate soon after RT of chemo-radiotherapy which correlates with a 95% probability of tumor control. This value is a very useful biomarker for guiding radiation therapy for the optimum outcome. For this study, over 100 patients have been enrolled.

3) FDG PET Imaging in Esophageal Cancer:
To correlate 18F-FDG uptake and tumor response in preoperative chemoradiotherapy and surgery.

4) Study of Neoadjuvant Chemo-Radiotherapy for Stage IIIA (N2) Non-Small Cell Lung Cancer:
To search for a radiation dose schedule higher than the conventional dose schedule of 45 Gy/25 F/5 weeks for better tumor downsizing, higher complete resection rate and improved 5-year survival rate in preoperative chemo-radiotherapy for marginally resectable stage IIIA (N2) non-small cell lung cancer. This is a phase I/II study in which the maximum tolerated dose (MTD) of radiation will be determined by a dose escalation schedule using a hybrid QD (to the initial target volume) and BID (to the gross target volume) radiation synchronized with chemotherapy cycles (cisplatin, 5-FU and Taxol). In phase II part of this study, the MTD of radiation will be tested for toxicities, tumor downstaging and survival.

Publications

View All Publications